TNF is a homoeostatic regulator of distinct epigenetically primed human osteoclast precursors.


Journal

Annals of the rheumatic diseases
ISSN: 1468-2060
Titre abrégé: Ann Rheum Dis
Pays: England
ID NLM: 0372355

Informations de publication

Date de publication:
06 2021
Historique:
received: 08 10 2020
revised: 31 12 2020
accepted: 25 01 2021
pubmed: 12 3 2021
medline: 28 6 2022
entrez: 11 3 2021
Statut: ppublish

Résumé

Circulating myeloid precursors are responsible for post-natal osteoclast (OC) differentiation and skeletal health, although the exact human precursors have not been defined. Enhanced osteoclastogenesis contributes to joint destruction in rheumatoid arthritis (RA) and tumour necrosis factor (TNF) is a well-known pro-osteoclastogenic factor. Herein, we investigated the interplay between receptor activator of nuclear factor kappa-Β ligand (RANK-L), indispensable for fusion of myeloid precursors and the normal development of OCs, and TNF in directing the differentiation of diverse pre-OC populations derived from human peripheral blood. Flow cytometric cell sorting and analysis was used to assess the potential of myeloid populations to differentiate into OCs. Transcriptomic, epigenetic analysis, receptor expression and inhibitor experiments were used to unravel RANK-L and TNF signalling hierarchy. TNF can act as a critical homoeostatic regulator of CD14 These findings fundamentally re-define the relationship between RANK-L and TNF. Moreover, they have identified a novel pool of human circulating non-MO OC precursors that unlike MOs are epigenetically preconditioned to ignore TNF-mediated signalling. In RA, this epigenetic preconditioning occurs in the MO compartment providing a pathological consequence of failure of this pathway.

Identifiants

pubmed: 33692019
pii: annrheumdis-2020-219262
doi: 10.1136/annrheumdis-2020-219262
pmc: PMC8142443
doi:

Substances chimiques

RANK Ligand 0
Tumor Necrosis Factor-alpha 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

748-757

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Cecilia Ansalone (C)

Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.

John Cole (J)

Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.

Sabarinadh Chilaka (S)

Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.

Flavia Sunzini (F)

Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.

Shatakshi Sood (S)

Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.

Jamie Robertson (J)

Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.

Stefan Siebert (S)

Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.

Iain B McInnes (IB)

Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.

Carl S Goodyear (CS)

Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK carl.goodyear@glasgow.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH